Acimtamig |
AFM-13 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides |
Details
|
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) |
|
Phase 2 Clinical |
Unc Lineberger Comprehensive Cancer Center |
Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Hodgkin Disease; Neoplasms; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms, Germ Cell and Embryonal |
Details
|
Itezocabtagene autoleucel |
TT-11; TT11 |
Phase 2 Clinical |
Tessa Therapeutics Ltd |
Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic |
Details
|
BRD-01 |
BRD-01 |
Phase 2 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms; Hodgkin Disease |
Details
|
GEN3017 |
GEN-3017 |
Phase 2 Clinical |
Genmab A/S |
Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous |
Details
|
HSP-CAR-30 |
HSP-CAR-30 |
Phase 2 Clinical |
Fundació Institut De Recerca De L |
Hodgkin Disease; Lymphoma, T-Cell |
Details
|
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) |
CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta |
Phase 2 Clinical |
Pla General Hospital |
Hodgkin Disease |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase 1 Clinical |
Immune Cell Inc |
Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic |
Details
|
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) |
TT-11X |
Phase 1 Clinical |
Baylor College Of Medicine, Tessa Therapeutics Ltd |
Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell |
Details
|
EBV-specific-CAR.CD30 |
EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System |
Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell |
Details
|
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 |
F0002-ADC; B-006 |
Phase 1 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd |
Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic |
Details
|
CD30.CAR |
H-27721; CD30.CAR |
Phase 1 Clinical |
Baylor College Of Medicine |
Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic |
Details
|
SGN-35C |
SGN-35C |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma |
Details
|
SGN-35T |
SGN-CD30C; PF-08046045; SGN-35T |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic |
Details
|
Anti-CD30 CAR-T cell therapy (National Cancer Institute) |
Hu30-CD28z |
Phase 1 Clinical |
National Cancer Institute |
Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma |
Details
|
PRA-052 |
PRA-052 |
Phase 1 Clinical |
Prometheus Biosciences Inc |
Colitis, Ulcerative |
Details
|
Anti CD30 CAR T Cell Therapy (First Song Therapeutics) |
|
Phase 1 Clinical |
Zhejiang University |
Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic |
Details
|
SGN-CD30C |
SGN-CD30C |
Phase 1 Clinical |
Seattle Genetics Inc |
Lymphoma |
Details
|
Acimtamig |
AFM-13 |
Phase 2 Clinical |
The University Of Texas MD Anderson Cancer Center |
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Mycosis Fungoides |
Details
|
ATLCAR.CD30 cells (UNC Lineberger Comprehensive Cancer Center) |
|
Phase 2 Clinical |
Unc Lineberger Comprehensive Cancer Center |
Lymphoma, T-Cell, Peripheral; Lymphatic Diseases; Immunoproliferative Disorders; Hodgkin Disease; Neoplasms; Immune System Diseases; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms, Germ Cell and Embryonal |
Details
|
Itezocabtagene autoleucel |
TT-11; TT11 |
Phase 2 Clinical |
Tessa Therapeutics Ltd |
Lymphoma, B-Cell; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic |
Details
|
BRD-01 |
BRD-01 |
Phase 2 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms; Hodgkin Disease |
Details
|
GEN3017 |
GEN-3017 |
Phase 2 Clinical |
Genmab A/S |
Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
CD30 biAb-AATC(The Medical College Of Wisconsin Nonprofit) |
|
Phase 2 Clinical |
The Medical College Of Wisconsin Nonprofit |
Lymphoma, B-Cell; Leukemia; Hodgkin Disease; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous |
Details
|
HSP-CAR-30 |
HSP-CAR-30 |
Phase 2 Clinical |
Fundació Institut De Recerca De L |
Hodgkin Disease; Lymphoma, T-Cell |
Details
|
Anti-CD30 CAR T-cell therapy (General Hospital of the People's Liberation Army/Cellular Biomedicine) |
CAR30-NKT; CBM-C30.1; CD30ScFv-CD8-CD137-CD3zeta |
Phase 2 Clinical |
Pla General Hospital |
Hodgkin Disease |
Details
|
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) |
|
Phase 2 Clinical |
Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd |
Pancreatic Neoplasms; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD30 chimeric antigen receptor T cell therapy (Immune cell) |
|
Phase 1 Clinical |
Immune Cell Inc |
Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic |
Details
|
CD30.CAR-EBVST cell therapy (Baylor College of Medicine) |
TT-11X |
Phase 1 Clinical |
Baylor College Of Medicine, Tessa Therapeutics Ltd |
Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell |
Details
|
EBV-specific-CAR.CD30 |
EBV-specific-CAR.CD30; CAR.CD30 EBV-specific-CTLs |
Phase 1 Clinical |
Baylor College Of Medicine, Texas Children'S Hospital, Methodist Hospital System |
Hodgkin Disease; Lymphoma, Non-Hodgkin |
Details
|
Anti-CD30 CAR T-cell therapy (Wuhan Bio-Raid) |
|
Phase 1 Clinical |
Wuhan BioRaid Biotechnology Co Ltd |
Hematologic Neoplasms; Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell |
Details
|
Recombinant chimeric anti-CD30 monoclonal antibody-MCC-DM1 |
F0002-ADC; B-006 |
Phase 1 Clinical |
Shanghai Crosslink Pharmaceutical R & D Co Ltd, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd |
Lymphoma, T-Cell, Peripheral; Hematologic Neoplasms; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic |
Details
|
CD30.CAR |
H-27721; CD30.CAR |
Phase 1 Clinical |
Baylor College Of Medicine |
Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Hodgkin Disease; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic |
Details
|
SGN-35C |
SGN-35C |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Large-Cell, Anaplastic; Lymphoma |
Details
|
SGN-35T |
SGN-CD30C; PF-08046045; SGN-35T |
Phase 1 Clinical |
|
Lymphoma, T-Cell, Peripheral; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Cutaneous; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Anaplastic |
Details
|
Anti-CD30 CAR-T cell therapy (National Cancer Institute) |
Hu30-CD28z |
Phase 1 Clinical |
National Cancer Institute |
Lymphoma, T-Cell, Peripheral; Enteropathy-Associated T-Cell Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large-Cell, Anaplastic; Lymphoma |
Details
|
PRA-052 |
PRA-052 |
Phase 1 Clinical |
Prometheus Biosciences Inc |
Colitis, Ulcerative |
Details
|
Anti CD30 CAR T Cell Therapy (First Song Therapeutics) |
|
Phase 1 Clinical |
Zhejiang University |
Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, T-Cell; Lymphoma, Large-Cell, Anaplastic |
Details
|
SGN-CD30C |
SGN-CD30C |
Phase 1 Clinical |
Seattle Genetics Inc |
Lymphoma |
Details
|